BMND02

BMND02 is a proprietary nasal formulation of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) developed by Biomind Labs. The drug utilizes a thermosensitive gel designed for intranasal delivery, which enhances mucosal membrane permeation and potentially allows for rapid onset of action. Preclinical in vitro assays have demonstrated positive drug permeation through the mucosal membrane. A pending patent application covers this specific formulation. The primary indication under evaluation is fibromyalgia, with the product positioned as a novel psychedelic-based therapy targeting neurological disorders[1][2][9].

Other names

5-MeO-DMT nasal formulation